E
BioCardia, Inc. BCDA
$2.14 -$0.40-15.75%
Recommendation
Sell
Prev Close
$2.80
Volume
224,761
Avg Vol (90D)
48,039
Market Cap
$13.10M
Dividend & Yield
--
52-Week Range
$1.63 - $6.30
P/E (TTM)
--
EPS (TTM)
-$3.85
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
BioCardia (BCDA) Reports Cost Cuts Amidst CardiAMP Trial Developments
4/1/2025 - GuruFocus
BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ...
4/1/2025 - GuruFocus
Q4 2024 BioCardia Inc Earnings Call Transcript
4/1/2025 - GuruFocus
Biocardia highlights promising CardiAMP-HF trial data with reduced mortality and improved quality of life
4/1/2025 - SeekingAlpha.com: All News
BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript
4/1/2025 - Seeking Alpha: Transcripts
BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript
4/1/2025 - SeekingAlpha
BioCardia Clarifies Timing for CardiAMP-HF Results Call
3/31/2025 - TipRanks Financial Blog
BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
3/31/2025 - GuruFocus
BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
3/31/2025 - Globe Newswire
BioCardia Reports Positive Phase 3 CardiAMP-HF Results
3/31/2025 - TipRanks Financial Blog
BioCardia's CardiAMP-HF trial primary endpoint did not reach significance
3/31/2025 - The Fly
Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure ...
3/31/2025 - GuruFocus
Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years
3/31/2025 - Globe Newswire
BioCardia (NASDAQ:BCDA) Posts Earnings Results
3/28/2025 - Ticker Report
BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
3/28/2025 - Simply Wall St
BioCardia Reports 2024 Business Highlights and Financial Results
3/26/2025 - GuruFocus
BioCardia Reports 2024 Business Highlights and Financial Results
3/26/2025 - Globe Newswire
What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings
3/25/2025 - GuruFocus
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
3/21/2025 - GuruFocus
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
3/21/2025 - Globe Newswire
BioCardia announces Japanese patent for Helix system
3/10/2025 - The Fly
BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System
3/10/2025 - Globe Newswire
Simon H. Stertzer Acquires 22,753 Shares of BioCardia, Inc. (NASDAQ:BCDA) Stock
3/6/2025 - MarketBeat
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for ...
2/27/2025 - GuruFocus
BioCardia finishes data freezing in heart failure therapy study for presentation
2/27/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$58.00K
EBITDA (TTM)
-$7.93M
EBIT (TTM)
-$8.00M
Net Income (TTM)
-$7.95M
Balance Sheet
Total Assets (Q)
$3.72M
Total Debt (Q)
$951.00K
Total Liabilities (Q)
$2.89M
Book Value Per Share (Q)
$0.1819
Cash Flow
Cash from Operations (TTM)
-$8.03M
Cash from Investing (TTM)
-$6.00K
Cash from Financing (TTM)
$9.30M
Net Change in Cash (TTM)
$1.27M
Filings
Filing Date
Wednesday, March 26, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
2.24
7-Day Total Return
-13.36%
30-Day Total Return
-24.65%
60-Day Total Return
-1.83%
90-Day Total Return
15.68%
Year to Date Total Return
-5.31%
1-Year Total Return
-63.97%
2-Year Total Return
-93.11%
3-Year Total Return
-93.27%
5-Year Total Return
-95.80%
52-week Low
Dec 19, 2024 - $1.63
52-week High
Apr 01, 2024 - $6.30
Valuation
Market Cap
$13.10M - Nano Cap
Enterprise Value
$11.68M
Price/Sales (TTM)
111.55
Price/Book (Q)
4.60
Dividends and Shares
Shares Outstanding
4.59M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.biocardia.com
Phone Number
650 226 0120
Address
320 Soquel Way
Sunnyvale, CA 94085
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product... more
NASDAQ 04/01/2025 4:00PM Eastern Quotes delayed
Weiss Ratings